Common pro-angiogenic factors include vascular endothelial growth factor (VEGF),24 fibroblast growth factors (FGFs),25 and angiopoietin-2 (ANGPT2),26 which promote endothelial cell migration, proliferation, and tube formation.27 Although anti-angiogenic therapies have been developed, their effectiveness is often limited due to compensatory mechanisms and resistance, highlighting the need for novel therapeutic strategies targeting angiogenesis in ESCC. Here, VEGFA is linked to esophageal squamous cell carcinoma.